APS Announces New Co-Leader for the Biopharmaceutics Focus Group

14 November 2024

After chairing the Biopharmaceutics Focus Group for a few years, Nikoletta Fotaki has decided to stand down. The APS are pleased to announce that Chris Roe will now be the Co-Leader of the Biopharmaceutics Focus Group alongside Chara Litou.

Chris Roe
Senior Research Fellow, Scientific Consulting,
Quotient Sciences

“I’m delighted to be joining Chara in leading the APS Biopharmaceutics Focus Group and honored to be following Nikoletta in this role which she has done brilliantly over the last few years. I’m looking forward to continuing the great work of the group in promoting scientific education, training and cross-sector pre-competitive collaboration within the field of biopharmaceutics through the group’s development and delivery of webinars, symposia and publications which extend our outreach, collaborating with the fantastic subject matter experts who are part of the group, and covering both oral and other extravascular routes of administration.

Overall, I’m just excited to be part of the journey in leveraging dynamic in vitro technologies, minimised/adaptive in vivo programs and in silico biopharmaceutical models to explore and risk assessing the relationships between the formulation of the drug, the route of administration and the physiological/biochemical environment within the body in support of efficient development of drugs with suitable exposure.”

The APS would like to thank Nikoletta for all her work with the Biopharmaceutics Focus Group and congratulate Chris on his appointment as Focus Group Co-Leader. If you would like to find out more about the Biopharmaceutics Focus Group or become a member, please do so here.